Data from Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer
Year: 2026
Type: other
Abstract: Purpose: Triple-negative breast cancer (TNBC) is a heterogeneous disease with high recurrence rates and poor prognosis, often requiring multiple therapies. BEGONIA was a phase Ib/II, multiarm, platform study evaluating the safety and efficacy of first-line treatment combinations with durvalumab (anti–PD-L1 antibody) for locally advanced, unresectable/metastatic TNBC (mTNBC; NCT03742102). In this study, we report results of 3 treatment arms. Patients and Methods: Eligible female participants (≥18 years with untreated, unresectable, locally advanced/mTNBC) received durvalumab plus paclitaxel or were randomized to this treatment in combination with capivasertib (pan-AKT inhibitor) or oleclumab (anti-CD73 antibody). The primary objective was safety and tolerability; secondary endpoints included objective response rate (ORR). Results: Twenty-three patients received durvalumab plus paclitaxel, 31 received capivasertib combination, and 33 received oleclumab combination. Maximum grade 3/4 adverse events occurred in 10 of 23 (43.5%), 25 of 31 (80.6%), and 8 of 33 (24.2%) patients in the durvalumab plus paclitaxel, capivasertib-combination, and oleclumab-combination arms, respectively. The confirmed ORR (95% confidence interval) was 56.5% (34.5–76.8) with durvalumab plus paclitaxel, 54.8% (36–72.7) with capivasertib combination, and 51.5% (33.5–69.2) with oleclumab combination. Responses were observed across biomarker subgroups, including PD-L1, PIK3CA/AKT1/PTEN alterations, and CD73, with a trend for improved activity in the PD-L1–positive subgroups. Conclusions: These findings support the clinical activity and tolerability of durvalumab plus paclitaxel in locally advanced unresectable/mTNBC, as expected for an immune checkpoint inhibitor in combination with chemotherapy. The addition of capivasertib or oleclumab to this treatment combination showed no substantial additional benefit. PD-L1 expression was associated with enhanced antitumor activity across all arms.
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W7203468114
Cites:
Cited by:
Related to: